{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:52:27Z","timestamp":1769734347804,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00432-018-2593-9","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T05:31:13Z","timestamp":1516685473000},"page":"637-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer"],"prefix":"10.1007","volume":"144","author":[{"given":"Francesca","family":"Sanguedolce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Massenio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Pedicillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Cagiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beppe","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Fino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantaleo","family":"Bufo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"key":"2593_CR1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461","journal-title":"Eur Urol"},{"key":"2593_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4081\/aiua.2013.2.73","volume":"85","author":"L Bongiovanni","year":"2013","unstructured":"Bongiovanni L, Arena V, Vecchio FM, Racioppi M, Bassi P, Pierconti F (2013) HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). Arch Ital Urol Androl 85:73\u201377","journal-title":"Arch Ital Urol Androl"},{"key":"2593_CR3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.11109","volume":"105","author":"JWF Catto","year":"2003","unstructured":"Catto JWF, Xinarianos G, Burton JL, Meuth M, Hamdy FC (2003) Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 105:484\u2013490","journal-title":"Int J Cancer"},{"key":"2593_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","volume":"66","author":"PC Chen","year":"2013","unstructured":"Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113\u2013119","journal-title":"J Clin Pathol"},{"key":"2593_CR5","first-page":"4201","volume":"29","author":"L Cormio","year":"2009","unstructured":"Cormio L, Tolve I, Annese P et al (2009) Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 29:4201\u20134204","journal-title":"Anticancer Res"},{"key":"2593_CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","volume":"28","author":"L Cormio","year":"2010","unstructured":"Cormio L, Tolve I, Annese P et al (2010) Retinoblastoma protein expression predicts response to bacillus Calmette\u2013Guerin immunotherpay in patients with T1G3 bladder cancer. Urol Oncol 28:285\u2013289","journal-title":"Urol Oncol"},{"key":"2593_CR7","doi-asserted-by":"crossref","first-page":"25433","DOI":"10.18632\/oncotarget.15989","volume":"8","author":"L Cormio","year":"2017","unstructured":"Cormio L, Sanguedolce F, Cormio A et al (2017a) Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget 8:25433\u201325441","journal-title":"Oncotarget"},{"key":"2593_CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.07.001","volume":"117","author":"A Cormio","year":"2017","unstructured":"Cormio A, Sanguedolce F, Musicco C et al (2017b) Mitochondrial dysfunctions in bladder cancer: exploring their role as disease markers and potential therapeutic targets. Crit Rev Oncol Hematol 117:67\u201372","journal-title":"Crit Rev Oncol Hematol"},{"key":"2593_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","volume":"11","author":"B Czerniak","year":"2016","unstructured":"Czerniak B, Dinney C, McConkey D (2016) Origins of bladder cancer. Annu Rev Pathol 11:149\u2013174","journal-title":"Annu Rev Pathol"},{"key":"2593_CR10","first-page":"4749","volume":"57","author":"W Dietmaier","year":"1997","unstructured":"Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J (1997) Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 57:4749\u20134756","journal-title":"Cancer Res"},{"key":"2593_CR11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","volume":"33","author":"W Ding","year":"2015","unstructured":"Ding W, Tong S, Gou Y et al (2015) Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33:1951\u20131957","journal-title":"World J Urol"},{"key":"2593_CR12","volume-title":"AJCC cancer staging manual","year":"2010","unstructured":"Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th\u00a0edn. Springer, New York","edition":"7"},{"key":"2593_CR13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<478::AID-CNCR28>3.0.CO;2-G","volume":"85","author":"TX Jin","year":"1999","unstructured":"Jin TX, Furihata M, Yamasaki M et al (1999) Human mismatch repair gene (hMSH2) product expression in relation to recurrence of transitional cell carcinoma of the urinary bladder. Cancer 85:478\u2013484","journal-title":"Cancer"},{"key":"2593_CR14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","volume":"21","author":"M La\u00e9","year":"2010","unstructured":"La\u00e9 M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815\u2013819","journal-title":"Ann Oncol"},{"key":"2593_CR15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/era.11.58","volume":"11","author":"RJ Lammers","year":"2011","unstructured":"Lammers RJ, Witjes JA (2011) Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853\u2013858","journal-title":"Expert Rev Anticancer Ther"},{"key":"2593_CR16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/carcin\/21.3.379","volume":"21","author":"KR Loeb","year":"2000","unstructured":"Loeb KR, Loeb LA (2000) Significance of multiple mutations in cancer. Carcinogenesis 21:379\u2013385","journal-title":"Carcinogenesis"},{"key":"2593_CR17","volume-title":"WHO classification of tumours of the urinary system and male genital organs","author":"H Moch","year":"2016","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification of tumours of the urinary system and male genital organs, 4th\u00a0edn. IARC, Lyon","edition":"4"},{"key":"2593_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0463.2008.00760.x","volume":"116","author":"E Mylona","year":"2008","unstructured":"Mylona E, Zarogiannos A, Nomikos A et al (2008) Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS 116:59\u201365","journal-title":"APMIS"},{"key":"2593_CR19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/carcin\/bgi298","volume":"27","author":"V O\u2019Brien","year":"2006","unstructured":"O\u2019Brien V, Brown R (2006) Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 27:682\u2013692","journal-title":"Carcinogenesis"},{"key":"2593_CR20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/00365599.2011.637955","volume":"46","author":"H Olsson","year":"2012","unstructured":"Olsson H, Fyhr IM, Hultman P, Jahnson S (2012) HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol 46:102\u2013107","journal-title":"Scand J Urol Nephrol"},{"key":"2593_CR21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette\u2013Guerin. Eur Urol 62:118\u2013125","journal-title":"Eur Urol"},{"key":"2593_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1383-5742(00)00058-2","volume":"488","author":"P Peltom\u00e4ki","year":"2001","unstructured":"Peltom\u00e4ki P (2001) DNA mismatch repair and cancer. Mutat Res 488:77\u201385","journal-title":"Mutat Res"},{"key":"2593_CR24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ejso.2004.04.015","volume":"30","author":"AA Saetta","year":"2004","unstructured":"Saetta AA, Goudopoulou A, Korkolopoulou P et al (2004) Mononucleotide markers of microsatellite instability in carcinomas of the urinary bladder. Eur J Surg Oncol 30:796\u2013803","journal-title":"Eur J Surg Oncol"},{"key":"2593_CR25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10408363.2014.930412","volume":"51","author":"F Sanguedolce","year":"2014","unstructured":"Sanguedolce F, Bufo P, Carrieri G, Cormio L (2014) Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 51:291\u2013304","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2593_CR26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10408363.2015.1033610","volume":"52","author":"F Sanguedolce","year":"2015","unstructured":"Sanguedolce F, Cormio A, Bufo P, Carrieri G, Cormio L (2015) Molecular markers in bladder cancer: novel research frontiers. Crit Rev Clin Lab Sci 52:242\u2013255","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2593_CR27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.juro.2006.09.038","volume":"177","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177:481\u2013487","journal-title":"J Urol"},{"key":"2593_CR28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2490-5-2","volume":"5","author":"M Vaish","year":"2005","unstructured":"Vaish M, Mandhani A, Mittal RD, Mittal B (2005) Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol 5:2","journal-title":"BMC Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2593-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T14:22:10Z","timestamp":1520518930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2593-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2593-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,23]]}}}